Schrodinger (SDGR) Competitors $20.59 -0.86 (-4.01%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$20.70 +0.11 (+0.53%) As of 10/3/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SDGR vs. CYTK, NUVL, CRSP, MTSR, TGTX, MRUS, PTCT, KRYS, MENS, and ARWRShould you be buying Schrodinger stock or one of its competitors? The main competitors of Schrodinger include Cytokinetics (CYTK), Nuvalent (NUVL), CRISPR Therapeutics (CRSP), Metsera (MTSR), TG Therapeutics (TGTX), Merus (MRUS), PTC Therapeutics (PTCT), Krystal Biotech (KRYS), Jyong Biotech (MENS), and Arrowhead Pharmaceuticals (ARWR). These companies are all part of the "pharmaceutical products" industry. Schrodinger vs. Its Competitors Cytokinetics Nuvalent CRISPR Therapeutics Metsera TG Therapeutics Merus PTC Therapeutics Krystal Biotech Jyong Biotech Arrowhead Pharmaceuticals Cytokinetics (NASDAQ:CYTK) and Schrodinger (NASDAQ:SDGR) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings. Do institutionals & insiders believe in CYTK or SDGR? 79.1% of Schrodinger shares are owned by institutional investors. 2.7% of Cytokinetics shares are owned by company insiders. Comparatively, 21.0% of Schrodinger shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Do analysts rate CYTK or SDGR? Cytokinetics presently has a consensus target price of $75.86, indicating a potential upside of 33.15%. Schrodinger has a consensus target price of $26.57, indicating a potential upside of 29.05%. Given Cytokinetics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Cytokinetics is more favorable than Schrodinger.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cytokinetics 1 Sell rating(s) 3 Hold rating(s) 12 Buy rating(s) 1 Strong Buy rating(s) 2.76Schrodinger 1 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.38 Which has stronger valuation & earnings, CYTK or SDGR? Schrodinger has higher revenue and earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Schrodinger, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCytokinetics$18.47M369.09-$589.53M-$5.10-11.17Schrodinger$207.54M7.30-$187.12M-$2.48-8.30 Which has more volatility & risk, CYTK or SDGR? Cytokinetics has a beta of 0.67, meaning that its share price is 33% less volatile than the S&P 500. Comparatively, Schrodinger has a beta of 1.74, meaning that its share price is 74% more volatile than the S&P 500. Is CYTK or SDGR more profitable? Schrodinger has a net margin of -76.22% compared to Cytokinetics' net margin of -707.17%. Cytokinetics' return on equity of 0.00% beat Schrodinger's return on equity.Company Net Margins Return on Equity Return on Assets Cytokinetics-707.17% N/A -45.52% Schrodinger -76.22%-45.70%-24.81% Does the media prefer CYTK or SDGR? In the previous week, Cytokinetics had 35 more articles in the media than Schrodinger. MarketBeat recorded 45 mentions for Cytokinetics and 10 mentions for Schrodinger. Schrodinger's average media sentiment score of 0.71 beat Cytokinetics' score of 0.20 indicating that Schrodinger is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytokinetics 6 Very Positive mention(s) 2 Positive mention(s) 31 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Schrodinger 2 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummarySchrodinger beats Cytokinetics on 10 of the 17 factors compared between the two stocks. Get Schrodinger News Delivered to You Automatically Sign up to receive the latest news and ratings for SDGR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SDGR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SDGR vs. The Competition Export to ExcelMetricSchrodingerMEDICAL INFO SYS IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.52B$2.28B$6.13B$10.58BDividend YieldN/AN/A5.65%4.69%P/E Ratio-8.3039.3386.9626.71Price / Sales7.3012.04605.32131.77Price / CashN/A60.2037.9061.31Price / Book3.5612.0512.556.55Net Income-$187.12M-$64.84M$3.31B$277.50M7 Day Performance6.68%3.27%4.28%2.42%1 Month Performance7.63%6.33%6.90%8.63%1 Year Performance17.59%34.71%70.54%31.60% Schrodinger Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SDGRSchrodinger3.3806 of 5 stars$20.59-4.0%$26.57+29.1%+17.6%$1.52B$207.54M-8.30790News CoverageAnalyst DowngradeCYTKCytokinetics3.8736 of 5 stars$48.25-0.8%$75.71+56.9%+0.5%$5.77B$85.74M-9.46250Trending NewsAnalyst ForecastInsider TradeNUVLNuvalent3.2701 of 5 stars$78.90+2.9%$119.50+51.5%-19.7%$5.69BN/A-16.1040Insider TradeCRSPCRISPR Therapeutics1.9274 of 5 stars$62.10-0.4%$71.50+15.1%+49.3%$5.65B$35M-11.44460News CoverageMTSRMetseraN/A$53.58+60.8%$63.50+18.5%N/A$5.63BN/A0.0081Analyst DowngradeGap UpHigh Trading VolumeTGTXTG Therapeutics4.3888 of 5 stars$34.97+8.0%$48.00+37.3%+65.1%$5.55B$454.07M94.51290MRUSMerus1.1222 of 5 stars$69.19+1.4%$90.54+30.9%+82.1%$5.23B$36.13M-12.5837Trending NewsAnalyst DowngradeOptions VolumeAnalyst RevisionPTCTPTC Therapeutics3.4226 of 5 stars$60.85+0.6%$69.00+13.4%+86.2%$4.83B$806.78M8.731,410KRYSKrystal Biotech4.6773 of 5 stars$165.42+1.1%$209.00+26.3%+3.5%$4.79B$359.21M33.62210Positive NewsMENSJyong BiotechN/A$59.53-9.3%N/AN/A$4.53BN/A0.0031High Trading VolumeARWRArrowhead Pharmaceuticals4.1691 of 5 stars$32.05+4.4%$43.14+34.6%+91.9%$4.43B$3.55M-25.04400Insider Trade Related Companies and Tools Related Companies CYTK Competitors NUVL Competitors CRSP Competitors MTSR Competitors TGTX Competitors MRUS Competitors PTCT Competitors KRYS Competitors MENS Competitors ARWR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SDGR) was last updated on 10/5/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredMelt-up warning Porter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in hi...Porter & Company | SponsoredThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top ad...Weiss Ratings | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Schrodinger, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Schrodinger With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SDGR Stock Alerts